Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Key claim: A phase I trial is evaluating the safety of the triple combination of navitoclax, venetoclax, and decitabine in patients with advanced myeloid malignancies including myelofibrosis.
Abstract
The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies.
The names of the drugs involved in this study are:
- Venetoclax
- Decitabine
- Navitoclax
Why this matters
Advanced/transformed PMF and MDS/MPN overlap remain among the worst-prognosis MPN states with no standard of care, and BCL-2/BCL-XL co-inhibition added to hypomethylation tests whether deeper apoptotic priming can overcome venetoclax-monotherapy resistance seen in myeloid disease. As a first-in-combination safety study, this trial expands the advanced-MPN therapeutic pipeline beyond JAKi+HMA and chemo-based bridging strategies and may inform subtype-specific tolerability of BCL-XL inhibition (notably thrombocytopenia) in fibrotic versus dysplastic-proliferative marrow contexts.